These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11904355)

  • 1. Iron overload and cardiovascular complications in dialysis patients.
    Kletzmayr J; Hörl WH
    Nephrol Dial Transplant; 2002; 17 Suppl 2():25-9. PubMed ID: 11904355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron overload as cardiovascular risk factor in children and adolescents with renal disease.
    Ruiz-Jaramillo Mde L; Guízar-Mendoza JM; Amador-Licona N; Gutiérrez-Navarro Mde J; Hernández-González MA; Dubey-Ortega LA; Solorio-Meza SE
    Nephrol Dial Transplant; 2011 Oct; 26(10):3268-73. PubMed ID: 21372265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cardiovascular morbidity and mortality risk factors in peritoneal dialysis patients].
    Jovanović DB
    Srp Arh Celok Lek; 2008; 136(5-6):313-8. PubMed ID: 18792634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosing and preventing iron overload.
    Ramanathan G; Olynyk JK; Ferrari P
    Hemodial Int; 2017 Jun; 21 Suppl 1():S58-S67. PubMed ID: 28328144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin hyporesponsiveness: from iron deficiency to iron overload.
    Tarng DC; Huang TP; Chen TW; Yang WC
    Kidney Int Suppl; 1999 Mar; 69():S107-18. PubMed ID: 10084294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review.
    Qunibi WY
    Arzneimittelforschung; 2010; 60(6a):399-412. PubMed ID: 20648931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Iron deficiency and overload. Implications in oxidative stress and cardiovascular health].
    Toxqui L; De Piero A; Courtois V; Bastida S; Sánchez-Muniz FJ; Vaquero MP
    Nutr Hosp; 2010; 25(3):350-65. PubMed ID: 20593115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels.
    Maruyama Y; Nakayama M; Yoshimura K; Nakano H; Yamamoto H; Yokoyama K; Lindholm B
    Nephrol Dial Transplant; 2007 May; 22(5):1407-12. PubMed ID: 17264097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload.
    Tarng DC; Huang TP
    Nephrol Dial Transplant; 1998 Nov; 13(11):2867-72. PubMed ID: 9829492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iatrogenic iron overload and its potential consequences in patients on hemodialysis.
    Rostoker G; Vaziri ND
    Presse Med; 2017 Dec; 46(12 Pt 2):e312-e328. PubMed ID: 29153377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron overload in hematopoietic cell transplantation.
    Majhail NS; Lazarus HM; Burns LJ
    Bone Marrow Transplant; 2008 Jun; 41(12):997-1003. PubMed ID: 18438425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxic effects of IV iron preparations in CKD patients.
    Vaziri ND
    Nephrol News Issues; 2014 Feb; 28(2):4-5. PubMed ID: 24649744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reassessment of Iron Biomarkers for Prediction of Dialysis Iron Overload: An MRI Study.
    Rostoker G; Griuncelli M; Loridon C; Magna T; Machado G; Drahi G; Dahan H; Janklewicz P; Cohen Y
    PLoS One; 2015; 10(7):e0132006. PubMed ID: 26182077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential risk for infection and atherosclerosis due to iron therapy.
    Sengoelge G; Sunder-Plassmann G; Hörl WH
    J Ren Nutr; 2005 Jan; 15(1):105-10. PubMed ID: 15648017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety Issues in Iron Treatment in CKD.
    Vaziri ND
    Semin Nephrol; 2016 Mar; 36(2):112-8. PubMed ID: 27236132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of anaemia in cardiovascular mortality and morbidity in transplant patients.
    Ponticelli C; Villa M
    Nephrol Dial Transplant; 2002; 17 Suppl 1():41-6. PubMed ID: 11812911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure; links to inflammation and oxidative stress.
    Stenvinkel P; Bárány P
    Nephrol Dial Transplant; 2002; 17 Suppl 5():32-7. PubMed ID: 12091605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study of intravenous ascorbic acid versus low-dose desferroxamine in patients on hemodialysis with hyperferritinemia.
    Deira J; Diego J; Martínez R; Oyarbide A; González A; Díaz H; Grande J
    J Nephrol; 2003; 16(5):703-9. PubMed ID: 14733417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of body iron stores with development of cardiovascular disease in the adult population: a systematic review of the literature.
    Zegrean M
    Can J Cardiovasc Nurs; 2009; 19(1):26-32. PubMed ID: 19226888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial.
    Zacharski LR; Chow BK; Howes PS; Shamayeva G; Baron JA; Dalman RL; Malenka DJ; Ozaki CK; Lavori PW
    JAMA; 2007 Feb; 297(6):603-10. PubMed ID: 17299195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.